GDUFA III: First-Cycle Approval, Priority Assessment Improvements Are Early Priorities
Executive Summary
Both issues have been the subject of questions and criticism as the FDA and industry attempt to boost generic competition.
You may also be interested in...
For ANDAs, Pre-Submission Facility Correspondence Has Improved, But Still Not Ideal
US FDA wants the program, intended to help speed ANDA approvals, utilized more, but industry still questions the information that must be submitted.
For ANDAs, Pre-Submission Facility Correspondence Has Improved, But Still Not Ideal
US FDA wants the program, intended to help speed ANDA approvals, utilized more, but industry still questions the information that must be submitted.
GDUFA III: US FDA Says Generic Drug Supplement Volume Could Require More Resources
Will the growing workload cause GDUFA fees to increase or prompt other changes?